Malignant melanoma: An update

Archives of Pathology and Laboratory Medicine

Volumn 125, Issue 10, 2001, Pages 1295-1306

  Slominski, A ^a   Wortsman, J ^a   Carlson, A J ^a   Matsuoka, L Y ^a   Balch, C M ^a   Mihm, M C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; CORTICOTROPIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MELANIN; GROWTH PROMOTOR;

ARTICLE; CANCER DIAGNOSIS; CANCER RESEARCH; CARCINOGENESIS; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MELANOGENESIS; MELANOMA; MELANOMA CELL; METASTASIS; PROGNOSIS; SKIN ULCER; TUMOR GROWTH; ULTRAVIOLET RADIATION; BIOSYNTHESIS; CHROMOSOME ABERRATION; CHROMOSOME DISORDER; DISEASE PREDISPOSITION; FEMALE; GENETIC PREDISPOSITION; IMMUNOTHERAPY; MALE; PATHOLOGY; PHYSIOLOGY; REVIEW;

CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; DISEASE SUSCEPTIBILITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GROWTH SUBSTANCES; HUMANS; IMMUNOTHERAPY; MALE; MELANINS; MELANOMA; NEOPLASM METASTASIS;

EID: 0034781113     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (168)

1. Molecular biology of human melanoma development and progression
2. Genetic predisposition to skin cancer
3. The pathogenesis of melanoma induced by ultraviolet radiation
4. Molecular pathology of malignant melanoma
5. Skin cancer
6. Current therapy for cutaneous melanoma
7. Management of cutaneous melanoma MO: State of the art and trends
8. Cutaneous melanoma: Pathology, relevant prognostic indicators and progression
9. Model predicting survival in stage I melanoma based on tumor progression
10. Lessons from tumor progression: The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent
11. Melanosomal proteins as melanoma-specific immune targets
12. Adjuvant therapy for cutaneous malignant melanoma
13. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens
14. Carbohydrate vaccines that induce antibodies against cancer, 2: Previous experience and future plans
15. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines
16. Clinical promise of tumor immunology
17. Immunological gene therapy approaches for malignant melanoma, 2: Preclinical studies and clinical strategies
18. Desmoplastic malignant melanoma
19. Desmoplastic neurotropic melanoma: A clinicopathologic analysis of 28 cases
20. A new American Joint Committee on Cancer staging system for cutaneous melanoma
21. The prognostic significance of ulceration of cutaneous melanoma
22. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial
23. Critical determinants of melanoma metastasis
24. Ultraviolet radiation A-induced precursors of cutaneous melanoma in monodelphis domestica
25. Role of ultraviolet radiation in the induction of melanocytic tumors in hairless mice following 7,12-dimenthylbenz (a) anthracene application and ultraviolet irradiation
26. Cytogenetics of melanocytic tumors
27. Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi
28. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus
29. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma
30. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas
31. Genetics of cutaneous malignant melanoma
32. Genetics of melanoma
33. INK4b genes as well as neighboring 9p21 markers, in sporadic melanoma
34. Loss of heterozygosity and homozygous deletions on 9q21-22 in melanoma
35. Cytogenetics in 158 patients with regional or disseminated melanoma: Subset analysis of near-diploid and simple karyotype
36. A malignant melanoma tumor suppressor on human chromosome 11
37. Loss of polymorphic restriction fragments in malignant melanoma: Implications for tumor heterogeneity
38. Differences in chromosomal aberrations between nodular and superficial spreading malignant melanoma detected by interphase cytogenetics
39. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma
40. Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma
41. Mechanisms of human melanoma cell growth and tumor suppression by chromosome 6
42. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6
43. Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma
44. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization
45. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma
46. The chromosome 10 monosomy common in human melanomas results from the loss of two separate tumor suppressor loci
47. Chromosome 10 allelic loss in malignant melanoma gene chromosomes
48. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts
49. Expression of NM23 in human melanoma progression and metastasis
50. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin
51. Involvement of the p16INK4 (CDKN2) gene in familial melanoma
52. Novel germline p16 mutation in familial melanoma in southern Sweden
53. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma
54. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds
55. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population
56. A cell cycle regulator potentially involved in genesis of many tumor types
57. Loss of expression of the pl6/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
58. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma
59. INK4 gene) during tumors progression in sporadic melanoma patients
60. Differential expression of the cyclin-dependent kinase inhibitors pl6 and p21 in the human melanocytic system
61. INK4a binding domain of CDK4 in familial melanoma
62. P53: At the crossroads of molecular carcinogenesis and molecular epidemiology
63. An abnormality in the p53 pathway following 8-irradiation in many wild-type p53 human melanoma lines
64. Modulation of p53 expression by human recombinant interferon-α2a correlates with abrogation of cisplatin resistance in a human melanoma cell line
65. Overexpression and mutations of p53 in metastatic malignant melanomas
66. Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas
67. Expression of c-kit encoded at the W locus of mice in developing embryonic germ cells and presumptive melanoblasts
68. On the potential role of proopiomelanocortin in skin physiology and pathology
69. Melanocortin and their implication in melanoma
70. Corticotropin releasing hormone and proopiomelanocortin involvement in cutaneous response to stress
71. Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone
72. Cutaneous neuromodulation the proopiomelanocortin system
73. Phosphorylated isomers of L-dopa stimulate MSH binding capacity and responsiveness to MSH in cultured melanoma cells
74. L-tyrosine stimulates induction of tyrosinase activity by MSH and reduces cooperative interactions between MSH receptors in hamster melanoma cells
75. Stimulation of melanocyte-stimulating hormone receptors by retinoic acid
76. UV light and MSH receptors
77. Animals under the sun: Effects of UV radiation on mammalian skin
78. Ultraviolet and melanocyte-stimulating hormone (MSH) stimulate mRNA production of αMSH receptors and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed keratinocytes
79. Interferons modulate the expression of hormone receptors on the surface of murine melanoma cells
80. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans
81. The Asp84Glu variant of the melanocortin 1 receptor (MC1 R) is associated with melanoma
82. Melanocortin-1 receptor gene and sun sensitivity in individuals without red hair
83. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype?
84. POMC gene expression in mouse and hamster melanoma cells
85. Detection of the proopiomelanocortin-derived antigens in normal and pathologic human skin
86. Immunoreactivity of α-melanocyte-stimulating hormone, adrenocorticotrophic hormone and β-endorphin in cutaneous malignant melanoma and benign melanocytic naevi
87. Immunoreactive α-melanotropin as an autocrine effector in human melanoma cells
88. Increased serum α-melanocyte stimulating hormone (α-MSH) in human malignant melanoma
89. bFGF as an autocrine growth factor for human melanomas
90. Growth factors and tyrosine protein kinases in normal and malignant melanocytes
91. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells
92. Human melanocyte growth and differentiation: A decade of new data
93. Signaling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes
94. Localization of basic fibroblast growth factor mRNA in melanocytic lesions by in situ hybridization
95. Expression of basic fibroblast growth factor in desmoplastic melanoma
96. Inhibition of proliferation of Cloudman S91 melanoma cells by insulin and characterization of some insulin-resistant variants
97. Evidence that a 90-kDa phosphoprotein, an associated kinase, and a specific phosphatase are involved in the regulation of Cloudman melanoma cell proliferation by insulin
98. Defect of insulin receptor in insulin-resistant variants of Cloudman S91 mouse melanoma cells
99. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas
100. Increased epidermal growth factor receptors in melanocytic lesions
101. Expression of transforming growth factor-β2 in malignant melanoma correlates with the depth of tumor invasion
102. In situ analysis of transforming growth factors-βs (TGF-β1, TGF-β2, TGF-β3), and TGF-β type II receptor expression in malignant melanoma
103. Melanoma-associated expression of transforming growth factor-β isoforms
104. Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas
105. Expression and distribution of transforming growth factor-α within melanocytic lesions
106. Analysis and significance of the malignant 'eclipse' during the progression of primary cutaneous human melanomas
107. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions
108. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer
109. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells
110. Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions
111. Interference with endogenous radioprotectors as a method of radiosensitization in "IAEA's Modification of Radiosensitivity of Biological Systems."
112. Some properties of Bomirski Ab amelanotic melanoma cells, which underwent spontaneous melanization in primary cell culture: Growth kinetics, cell morphology, melanin content and tumorigenicity
113. Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle
114. Pharmacological disruption of hair follicle pigmentation as a model for studying the melanocyte response to and recovery from cytotoxic damage in situ
115. Eumelanins and pheomelanins: Characterization by electron spin resonance spectroscopy
116. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: Selective review and hypothesis
117. Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis
118. Sister chromatid exchange (SCE) rates in human melanoma cells as an index of mutagenesis
119. Melanocytotoxicity and antimelanoma effects of phenolic amine compounds in mice in vivo
120. Melanogenesis: A realistic target for antimelanoma therapy?
121. Melanocytes as sensory and regulatory cells in the epidermis
122. Regulation of melanogenesis in melanocytes
123. The natural history of a family of transplantable melanomas in hamsters
124. Abnormal melanosomes: Ultrastructural markers of melanocytic atypia
125. Pathology and ultrastructural characteristics of a hypomelanotic variant of transplantable hamster melanoma with high tyrosinase activity
126. Possible relationship between abnormal melanosome structure and cytotoxic phenomena in malignant melanoma
127. Cyto-genotoxic species leakage with human melanoma melanosomes, molecular-morphological correlation
128. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution
129. Molecular mechanism governing melanogenesis in hamster melanomas: Relative abundance of tyrosinase and catalase-B (gp 75)
130. Detection of tyrosinase mRNA in formalin-fixed, paraffin-embedded archival sections of melanoma, using the reverse transcriptase in situ polymerase chain reaction
131. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: Frequency and distribution
132. Microphthalmia transcription factor a sensitive and specific melanocyte marker for melanoma diagnosis
133. Detection of occult melanoma cells in blood with multiple-marker polymerase chain reaction assay
134. Molecular staging of malignant melanoma
135. Molecular detection of micrometastases and circulating tumor cells in solid tumors
136. Polymerase chain reaction detection of mela-anoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma
137. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma
138. Minimally invasive staging of patients with melanoma-sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction
139. Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry
140. High plasma levels of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma
141. Evaluation of melanin-related metabolites as markers of melanoma progression
142. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma
143. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy
144. Tyrosinase activity in the serum of patients with malignant melanoma
145. Serum tyrosine hydroxylase activity is increased in melanoma patients - An ROC curve analysis
146. Inhibition of melanogenesis for melanoma therapy?
147. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanoma
148. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
149. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
150. Identification of the immunodominant peptiaes of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 -restricted tumor infiltrating lymphocytes
151. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
152. Analysis of the antibody response to immunization with purified 0-acetyl GD3 gangliosides in patients with malignant melanoma
153. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
154. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides
155. On course for a cancer vaccine
156. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography
157. Ganglioside GM3:GD3 ratio as an index for the management of melanoma
158. Glycosphingolipids in Bomirski transplantable melanomas in hamsters
159. Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoglanglioside GD3
160. Melanoma-associated antigens
161. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions
162. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis